← Back to patent-cliff list
YJ001
Tier C — Watch / tradeYJ001
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：糖尿病周围神经性疼痛, 糖尿病周围神经病变, Diabetic neuropathy
Regional status
US
Phase I
2022-08-15
EU
-
China
Phase III
2026-05-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of YJ001?
Approved indications include: 糖尿病周围神经性疼痛, 糖尿病周围神经病变, Diabetic neuropathy.
When does the YJ001 patent expire?
No public expiry year is available for YJ001 yet; this page updates once verified.
How do I get a quote for YJ001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29